光正眼科医院集团股份有限公司 证券代码：002524 证券简称：光正眼科 公告编号：2024-053 一、审议并通过《关于向 2023 年限制性股票激励计划激励对象授予预留限 制性股票的议案》 光正眼科医院集团股份有限公司 第五届监事会第二十三次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 光正眼科医院集团股份有限公司（以下简称"公司"）第五届监事会第二十 三次会议于2024年8月29日（星期四）以现场结合通讯方式召开。会议应参与表 决监事3人，实际参与表决监事3人。本次会议由监事会主席杨红新先生主持，会 议的召集、召开程序及参加表决的监事人数符合《公司法》《公司章程》等有关 法律、法规的规定，合法、有效。经与会监事认真审议，形成如下决议： 经审核，监事会认为本次拟授予限制性股票的激励对象均符合《上市公司股 权激励管理办法》等规范性文件规定的激励对象条件，激励对象中无公司独立董 事、监事和单独或合计持有公司 5%以上股份的股东或实际控制人及其配偶、父 母、子女。本次被授予限制性股票的激励对象主体资格合法、有效，满足获授限 制性股票的条件。同意将 ...

证券代码：002524 证券简称：光正眼科 公告编号：2024-052 光正眼科医院集团股份有限公司 光正眼科医院集团股份有限公司 表决结果：同意 6 票；反对 0 票；弃权 0 票；回避 3 票。 本议案已经董事会薪酬与考核委员会审议通过。 备查文件： 1.第五届董事会第二十八次会议决议 特此公告。 第五届董事会第二十八次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 光正眼科医院集团股份有限公司（以下简称"公司"）第五届董事会第二十 八次会议于 2024 年 8 月 29 日（星期四）以现场结合通讯方式召开。本次会议应 参与表决董事9人，实际参与表决董事9人，公司部分高级管理人员列席了会议， 会议由董事长周永麟先生主持，会议的召集、召开程序及参加表决的董事人数符 合《公司法》、《公司章程》等有关法律、法规的规定，合法、有效。经与会董 事认真审议本次会议议案并表决，形成本次董事会决议如下： 一、审议通过《关于向 2023 年限制性股票激励计划激励对象授予预留限制 性股票的议案》 公司《2023 年限制性股票激励计划（草案）》已经公司 2023 ...

光正眼科医院集团股份有限公司监事会 （4）具有《公司法》规定的不得担任公司董事、高级管理人员情形的； （5）法律法规规定不得参与上市公司股权激励的； （6）中国证监会认定的其他情形。 关于公司2023年限制性股票激励计划预留授予 激励对象名单（授予日）的核查意见 光正眼科医院集团股份有限公司（以下简称"公司"）监事会依据《中华人民 共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下 简称"《证券法》"）、《上市公司股权激励管理办法》（以下简称"《管理办法》"） 和《光正眼科医院集团股份有限公司章程》（以下简称"《公司章程》"）等有关 规定，对公司2023年限制性股票激励计划（以下简称"本次激励计划"）预留授予 激励对象名单（授予日）进行了核查，发表核查意见如下： 1、本次激励计划拟获授权益的激励对象均不存在《管理办法》第八条规定 的不得成为激励对象的如下情形： （1）最近12个月内被证券交易所认定为不适当人选； （2）最近12个月内被中国证监会及其派出机构认定为不适当人选； （3）最近12个月内因重大违法违规行为被中国证监会及其派出机构行政处 罚或者采取市场禁入措施； 监事签名： 杨红新 ...

2、本激励计划激励对象不包括独立董事、监事，也不包括单独或合计持有公司 5.00%以上股份 的股东或实际控制人及其配偶、父母、子女； 3、上表中数值若出现总数与各分项数值之和尾数不符，均为四舍五入原因所致。 二、激励对象名单 | 序号 | 姓名 | 职务 | | --- | --- | --- | | 1 | 柳林 | 中层管理人员及核心骨干员工 | | 2 | 庞天策 | 中层管理人员及核心骨干员工 | | 3 | 黄小敏 | 中层管理人员及核心骨干员工 | 光正眼科医院集团股份有限公司 2023 年限制性股票激励计划预留授予激励对象名单（授予日） | 一、激励对象获授的限制性股票分配情况 | | --- | | | | 获授的限制 | 占授予限制 | 占公司当前股 | | --- | --- | --- | --- | --- | | 姓名 | 职务 | 性股票数量 | 性股票总数 | 本总额的比例 | | | | （万股） | 的比例 | | | 中层管理人员及核心骨干员工（3 | 人） | 60 | 7.49% | 0.12% | | 预留授予部分合计（3 | 人） | 60 | 7.49% | 0. ...

光正眼科医院集团股份有限公司 证券代码：002524 证券简称：光正眼科 公告编号：2024-054 预留限制性股票的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 1.限制性股票预留授予日：2024 年 8 月 29 日 光正眼科医院集团股份有限公司（以下简称"光正眼科"或"公司"）2023 年限制性股票激励计划（以下简称"本次激励计划"或"本激励计划"）规定的 预留授予条件已经成就，根据公司 2023 年度第三次临时股东大会的授权，公司 于 2024 年 8 月 29 日召开了第五届董事会第二十八次会议和第五届监事会第二十 三次会议，审议通过了《关于向 2023 年限制性股票激励计划激励对象授予预留 限制性股票的议案》。董事会同意将预留授予日确定为 2024 年 8 月 29 日，以人 民币 1.62 元/股的授予价格向符合授予条件的 3 名激励对象授予 60 万股限制性 股票。具体情况如下： 一、2023 年限制性股票激励计划简述 （一）激励工具及标的股票来源 本次激励计划采取的激励工具为限制性股票，其股票来源为光正眼科从二级 市场 ...

| | | | | 2024 年初 | 2024 半年度 | 2024 半年度 | 2024 | 半年度 | 2024 年 6 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资 | 资金占用方名称 | 占用方与上市公 | 上市公司核算的 | 占用资金 | 占用累计发 | 占用资金的 | 偿还累计发 | | 月 30 日占 | 占用形成 | 占用性质 | | 金占用 | | 司的关联关系 | 会计科目 | | 生金额（不含 | | | | 用资金余 | 原因 | | | | | | | 余额 | 利息） | 利息（如有） | 生额 | | 额 | | | | 现大股东及 | | | | | | | | | | | | | 其附属企业 | | | | | | | | | | | | | 小 计 | —— | —— | —— | - | - | | - | - | - | —— | —— | | 前大股东及 | | | | | | | | | | | | | 其附属企业 | | | | | ...

Financial Performance - The company's operating revenue for the first half of 2024 was ¥481,903,187.33, a decrease of 11.81% compared to ¥546,407,836.66 in the same period last year[11]. - The net profit attributable to shareholders for the first half of 2024 was ¥1,273,940.73, down 75.37% from ¥5,172,240.93 in the previous year[11]. - The net profit after deducting non-recurring gains and losses was -¥6,658,854.46, a decline of 263.27% compared to ¥4,078,548.93 in the same period last year[11]. - The basic earnings per share for the first half of 2024 was ¥0.00, a decrease of 100.00% compared to ¥0.01 in the same period last year[11]. - The diluted earnings per share also stood at ¥0.00, down 100.00% from ¥0.01 in the previous year[11]. - The weighted average return on equity was 0.44%, down 1.45% from 1.89% in the same period last year[11]. - The company reported a net profit of CNY 762,587.17 from its subsidiary Shanghai Guangzheng New Vision Eye Hospital Investment Co., Ltd.[41]. - The company reported a net loss of CNY -298,438,952.14, slightly improved from CNY -299,712,892.87 in the previous period[116]. - The total comprehensive income for the first half of 2024 was -6,516,188.77, an improvement from -17,424,512.45 in the first half of 2023[125]. Cash Flow and Liquidity - The net cash flow from operating activities increased significantly to ¥39,051,358.84, up 2,386.00% from ¥1,570,850.18 in the previous year[11]. - The net cash flow from operating activities for the first half of 2024 was ¥3,164,735.17, a significant improvement compared to a net outflow of ¥17,097,638.63 in the same period of 2023[129]. - The total cash inflow from operating activities for the first half of 2024 was 489,286,494.14, up from 481,256,452.35 in the first half of 2023[126]. - The cash and cash equivalents at the end of the first half of 2024 amounted to 112,310,149.89, an increase from 72,087,149.12 at the end of the first half of 2023[126]. - The cash flow from operating activities showed a positive trend, indicating improved operational efficiency compared to the previous year[129]. - The total cash and cash equivalents at the end of the period reached ¥48,021,967.18, up from ¥12,389,313.92 at the end of the same period in 2023[129]. Revenue Breakdown - Revenue from the medical sector was 417.12 million yuan, a slight increase of 0.70% from 414.24 million yuan year-on-year, accounting for 86.56% of total revenue[23]. - The steel structure sector's revenue fell significantly by 61.04% to 46.34 million yuan from 118.95 million yuan year-on-year, representing 9.62% of total revenue[23]. - The energy sector saw a revenue increase of 39.42% to 18.44 million yuan from 13.22 million yuan year-on-year, making up 3.82% of total revenue[23]. - The medical industry contributed ¥417,122,309.37, accounting for 86.56% of total revenue, showing a slight increase of 0.70% from ¥414,238,161.51 in the previous year[32]. - The refractive project generated CNY 142,209,658.24 in revenue, down 14.12% compared to the previous year, with a gross margin of 43.99%[34]. - The cataract project saw revenue of CNY 160,887,690.23, an increase of 5.66% year-on-year, with a gross margin of 52.39%[34]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,551,723,221.55, reflecting a slight increase of 0.15% from ¥1,549,365,088.25 at the end of the previous year[11]. - The total liabilities decreased to CNY 1,256,778,765.10 from CNY 1,263,462,691.96, a reduction of approximately 0.5%[116]. - The company's total equity attributable to shareholders increased to CNY 292,492,217.12 from CNY 283,257,684.81, reflecting a growth of about 3.4%[116]. - The company's long-term equity investments increased to CNY 1,915,557,118.89 from CNY 1,908,949,669.71, a growth of about 0.4%[118]. - The company's cash and cash equivalents rose to CNY 48,021,967.18 from CNY 25,039,335.16, an increase of approximately 91.6%[117]. Strategic Focus and Development - The company is focusing on high-quality and stable development by enhancing the standardized operational processes in its ophthalmology services[24]. - The company is promoting the transition to high-end cataract surgeries, such as femtosecond cataract and refractive cataract surgeries, to meet the increasing quality demands of patients[25]. - The company aims to strengthen its competitive position by implementing a regional strategy targeting major urban clusters, including the Yangtze River Delta and the Beijing-Tianjin-Hebei region[45]. - The company is committed to social responsibility, engaging in various public welfare projects to improve eye health in underserved communities[30]. - The company is actively involved in the research and development of assembly-type steel structure buildings, contributing to the green and low-carbon construction industry[18]. Talent and Management - The company has established a competitive compensation system and implemented a restricted stock incentive plan to stabilize its talent pool and enhance entrepreneurial motivation[22]. - The company has established a talent reserve mechanism combining internal training and external recruitment to address the increasing demand for skilled medical professionals[46]. - The company has strengthened its management system and operational efficiency through the integration of advanced medical management experiences and operational models[21]. - The company emphasizes a marketing model that combines centralized brand management with localized marketing strategies tailored to regional characteristics[15]. - The company has a strong core competitiveness in technology, service, brand, scale, talent, research, and management within the ophthalmology industry[17]. Environmental and Social Responsibility - The company has not faced any administrative penalties related to environmental issues during the reporting period[60]. - The company adheres to various environmental protection laws and regulations, ensuring compliance in its operations[60]. - The company has established a comprehensive wastewater discharge system and strictly implements environmental protection measures across all hospitals[64]. - During the reporting period, the company conducted charitable activities in impoverished areas, including cataract surgeries in Qinghai Province[64]. - The company has actively collaborated with various charitable organizations to support social welfare projects[64]. Legal and Compliance - The company has no significant litigation or arbitration matters during the reporting period[70]. - The company has not engaged in any non-compliance external guarantees during the reporting period[68]. - The company’s half-year financial report has not been audited[69]. - The financial report was approved by the board of directors on August 26, 2024, ensuring compliance with relevant regulations[141]. - The company adheres to the accounting standards set by the Ministry of Finance, ensuring accurate financial reporting[146]. Shareholder and Equity Management - The company plans not to distribute cash dividends or issue bonus shares for this reporting period[2]. - The company held its annual general meeting with a participation rate of 26.57% and approved multiple key proposals, including the annual financial report and profit distribution plan[50]. - The company has a total of 14,462 square meters leased for hospital operations in Shanghai, ensuring adequate space for administrative functions[79]. - The company has a total of 6,056 square meters leased in Shanghai for hospital operations, further supporting its operational needs[79]. - The company’s stock incentive plan includes provisions for repurchase and unlocking based on performance and tenure[104].

光正眼科医院集团股份有限公司 证券代码：002524 证券简称：光正眼科 公告编号：2024-049 光正眼科医院集团股份有限公司 关于下属子公司综合授信及担保事项的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、概述 光正眼科医院集团股份有限公司（以下简称"公司"）于 2024 年 4 月 23 日召开第五届董事会第二十四次会议和第五届监事会第十九次会议，分别审议通 过了《关于公司、子公司及其下属公司 2024 年度向银行等相关金融机构申请综 合授信额度并提供担保的议案》，同意根据公司 2024 年度生产经营计划和发展 规划，公司及控股子公司拟将向银行等相关金融机构申请总额不超过 7 亿元的综 合授信，公司、控股子公司及其下属公司间为上述综合授信提供累计不超过 6.5 亿元(含)的担保额度，授信及担保额度的有效期自 2023 年度股东大会审议通过 之日起 12 个月内有效。具体内容详见 2024 年 4 月 25 日公司发布在《证券时报》 及巨潮资讯网（http://www.cninfo.com.cn）的公告（公告编号：2024-021）。 2 ...

光正眼科医院集团股份有限公司 2.经中国证券登记结算有限责任公司深圳分公司审核确认，公司本次限制性股票回购注 销事宜已于2024年8月22日办理完成。 一、本次限制性股票激励计划的具体情况 1.2019 年 4 月 30 日，公司召开第四届董事会第十二次会议，审议通过了关 于《2019 年限制性股票激励计划（草案）》及《2019 年限制性股票激励计划实 施考核管理办法》等相关议案,公司独立董事对本次激励计划的相关议案发表了 独立意见。 2.2019 年 4 月 30 日，公司召开第四届监事会第七次会议，审议通过了关于 《2019 年限制性股票激励计划（草案）》及《2019 年限制性股票激励计划实施 考核管理办法》等相关议案。 3.2019 年 5 月 6 日至 2019 年 5 月 16 日，公司对本次授予激励对象的名单 在公司内网进行了公示，在公示期内，公司监事会未接到与激励计划拟激励对象 有关的任何异议。2019 年 5 月 18 日，公司监事会披露了《关于公司 2019 年限 制性股票激励计划首次授予部分激励对象名单公示情况的说明及审核意见》。 证券代码：002524 证券简称：光正眼科 公告编号：20 ...

Financial Performance - The estimated net profit attributable to shareholders for the first half of 2024 is projected to be between 1 million and 1.5 million yuan, representing a decline of 71.00% to 80.67% compared to the same period last year, which was 5.1722 million yuan [3]. - The net profit after deducting non-recurring gains and losses is expected to be between -7.5 million and -6.5 million yuan, a decrease of 259.37% to 283.89% from 4.0785 million yuan in the previous year [3]. - Basic earnings per share are projected to be between 0.00 yuan and 0.00 yuan, down from 0.01 yuan in the same period last year [3]. Revenue Performance - The company's ophthalmology business revenue remained stable compared to the previous year, while the steel structure segment's revenue fell short of expectations due to external economic conditions, leading to a slight overall decrease in revenue [5]. Cost and Expenses - Increased sales expenses and higher stock incentive costs from a new round of equity incentives implemented in 2023 contributed to the decline in net profit compared to the previous year [5]. Financial Reporting - The financial data presented is based on preliminary estimates by the company's finance department and has not been audited by an accounting firm [4]. - Investors are advised to make cautious decisions and be aware of investment risks as the final financial data will be disclosed in the company's 2024 semi-annual report [6].